|
US2021104038A1
|
|
Retained Surgical Items
|
|
WO2021026349A1
|
|
Combination therapy for treatment of cancer
|
|
WO2020247353A1
|
|
Adeno-associated virus vector delivery of cystathionine beta-synthase (cbs) enzyme for treating cbs deficiency
|
|
WO2020243063A1
|
|
Pi3k/lyn-acly signaling inhibition
|
|
WO2020223273A2
|
|
Compositions and methods for modulation of antibody activity
|
|
WO2020219854A1
|
|
Netrin g1 and netrin g1 ligand peptides and antibodies and uses thereof
|
|
WO2020167927A1
|
|
Antibodies to cell adhesion molecule-related/down-regulated by oncogenes (cdon) and uses thereof
|
|
WO2020092517A1
|
|
Combination therapies for treating cancer
|
|
WO2020046770A1
|
|
Kinase activity in tumors
|
|
WO2020046769A1
|
|
Hematostick/hematodart
|
|
WO2019222325A1
|
|
Urinary dna detection for urothelial cancer
|
|
WO2019177928A1
|
|
Mir-3132 upregulation of the trail pathway and apoptotic activity in cancer cells
|
|
WO2019157488A1
|
|
Tensionable surgical clamp
|
|
US2019249215A1
|
|
Three-Dimensional Cell-Derived Extracellular Matrix/Gel Systems
|
|
US2021038842A1
|
|
Multipurpose Device
|
|
US2019225613A1
|
|
Compounds For Repressing Cancer Cell Growth
|
|
WO2019079167A1
|
|
Human chorionic gonadotropin variant peptides and treatment of breast cancer
|
|
WO2019074915A1
|
|
Netrin g1 as a biomarker for enhancing tumor treatment efficacy
|
|
WO2019005764A1
|
|
Mhc-1 genotype restricts the oncogenic mutational landscape
|
|
WO2018218114A1
|
|
Use of cholesterol for promoting survival and proliferation of primary medulloblastoma cells
|
